We are looking for an experienced code of ethics reviewer to join our team. Applicants are expected to have M.Sc. in the field of life science/medical science/pharmacy. The position requires knowledge in the pharma industry ethical code and its’ application in the industry-related activities. Also, solution-oriented, proactive, collaborative and independent working style are necessary personal qualities in this role. Excellent communication skills are needed to successfully run the tasks. The position is interim for a 12-month period with a potential for prolongation. Fluency in Finnish (both written and oral) is necessary.
Medaffcon offers a position in a non-hierarchical and supportive team environment with the possibility to gain experience in the pharmaceutical industry. The person will be working with cross-functional teams within various therapeutic areas such as oncology and immunology in our customer company. Also, the employee enjoys fully Medaffcon’s employment benefits. While working for our client, the outsourced employee is part of the Medaffcon team and has the opportunity to participate in activities such as the company’s innovative days and breakfast moments.
We provide comprehensive training in our procedures and processes as well as a Medaffcon team’s support in the role.
The adoption of new diabetes medications in Finland was active between 2012 and 2019, according to an RWE (Real World Evidence) study published in May 2024. The study was conducted by Medaffcon in collaboration with the pharmaceutical company Sanofi.
In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, RWE studies (Real World Evidence).
Lung cancer is the leading cause of cancer deaths in Finland, with a particularly poor prognosis for non-small cell lung cancer (NSCLC). It is often diagnosed at an advanced stage when treatment options are limited. A recently published retrospective registry-based real-world evidence (RWE) study on KRAS-mutated NSCLC patients in Finland addressed this issue.